UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.05 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 39,402,619 shares of the biopharmaceutical company's stock after purchasing an additional 1,333,740 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.70% of Pfizer worth $1,045,351,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter worth about $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on PFE. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.46 during midday trading on Wednesday, reaching $23.06. The company's stock had a trading volume of 42,933,836 shares, compared to its average volume of 41,086,139. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average price of $23.50 and a 200 day moving average price of $25.25. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market cap of $131.10 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.46%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.